There are contradictory publications and reports regarding the dependence liability of the 3-hydroxy-benzo-1,4-diazepine derivative lormetazepam, one of the most often prescribed hypnotic benzodiazepines which is now also available as an intravenous (i.v.) product for anesthetists. The author was involved in the preclinical and subsequently in the clinical development and post-marketing surveillance of lormetazepam. Here, he reviews the published and unpublished data about lormetazepam dependence and proposes explanations for contradictory views from other authors. On this basis and in contrast to class labeling from regulatory bodies and WHO, the author comes to the conclusion that use of lormetazepam definitely carries a lower risk of inducing dependence and causing abuse than most other benzodiazepines. This applies as well to Sedalam^®, the new i.v. application form of lormetazepam, which is much better tolerated than propofol. Because of its pharmacokinetic properties and because all its effects can be fully antagonized with the benzodiazepine antagonist flumazenil, this innovative intravenous application form of lormetazepam provides an excellent method for premedication, symptomatic treatment of excitation and anxiety in the context of surgical or diagnostic procedures including outpatient interventions and for basic sedation during anesthesia.

关于 3-羟基-苯并-1,4-二氮杂卓衍生物氯甲西泮的依赖性问题存在相互矛盾的出版物和报告，氯甲西泮是最常用的安眠药之一，现在也可作为麻醉师的静脉注射 (iv) 产品使用。作者参与了氯甲西泮的临床前和随后的临床开发和上市后监测。在这里，他回顾了有关氯甲西泮依赖的已发表和未发表的数据，并就其他作者的矛盾观点提出了解释。在此基础上，与监管机构和世界卫生组织的类别标签相比，作者得出的结论是，与大多数其他苯二氮卓类药物相比，使用氯美西泮绝对具有较低的诱导依赖和滥用风险。这也适用于 Sedalam^®，氯美西泮的新静脉注射剂型，比丙泊酚耐受性好得多。由于其药代动力学特性，并且其所有作用都可以与苯二氮卓类拮抗剂氟马西尼完全拮抗，这种创新的氯美西泮静脉应用形式为手术或诊断程序（包括门诊患者）的术前用药、兴奋和焦虑的对症治疗提供了一种极好的方法干预和麻醉期间的基本镇静。